Skip to content
value.today

Ignyta, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2012
Total raised
$84 M
3 rounds on record
Latest round
$30 M
Nov 2015
First round on record
Nov 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Ignyta, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2015$30 MNo. 3$10 to $50 million

Ignyta, Inc.: Raise no. 3, Nov 2015

Investors in this round

1 investor had bought by the notice of Nov 16, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $39 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard E. Parker · Executive Officer · Chief Commercial Officer
  • Igor P. Bilinsky, Ph.D. · Executive Officer · General Manager, Immuno-Oncology and Senior Vice President, Special Operations
  • Jacob E. Chacko, M.D. · Executive Officer · Chief Financial Officer
  • Jonathan E. Lim, M.D. · Executive Officer, Director · President and Chief Executive Officer
  • Matt E. Onaitis, J.D. · Executive Officer · Secretary and General Counsel
  • Pratik S. Multani, M.D. · Executive Officer · Chief Medical Officer
  • Robert E. Wild, Ph.D. · Executive Officer · Chief Scientific Officer and SVP, Research
  • Valerie S. Harding, Ph.D. · Executive Officer · Senior Vice President, Chemistry, Manufacturing and Controls
  • Zachary E. Hornby · Executive Officer · Chief Operating Officer
  • Alex E. Casdin · Director
  • Heiner E. Dreismann, Ph.D. · Director
  • James E. Bristol, Ph.D. · Director
  • James E. Freddo, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan E. Lim, M.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 16, 2015. Read the notice at the SEC.

equitySEC
Nov 2013$8 MNo. 2$2 to $10 million

Ignyta, Inc.: Raise no. 2, Nov 2013

Investors in this round

195 investors had bought by the notice of Dec 9, 2013: 195 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$12,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$635,960
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jonathan Lim · Executive Officer, Director
  • Patrick O'Connor · Executive Officer
  • Zachary Hornby · Executive Officer
  • Alexander Casdin · Director
  • Heinrich Dreismann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · Seattle, WashingtonSold in AL, AR, AZ, CA, CO, CT, FL, GA, IL, IN, KY, LA, MA, MD, MI, MN, MO, NC, ND, NE, NJ, NY, OK, OR, PA, TN, TX, UT, VA, WA, WI

Remarks in the notice

  • On the use of proceeds: “The proceeds from the private offering will be used for general working capital purposes, including payments to employees. The officers listed in Item 3 will be among the employees whose salaries may be paid from a portion of the proceeds.”

Signed by Zachary Hornby, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 9, 2013. Read the notice at the SEC.

equitySEC
Nov 2013$46 MNo. 1$10 to $50 million

Ignyta, Inc.: Raise no. 1, Nov 2013

Investors in this round

52 investors had bought by the notice of Nov 12, 2013: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,255,350
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jonathan Lim · Executive Officer, Director
  • Patrick O'Connor · Executive Officer
  • Zachary Hornby · Executive Officer
  • Alexander Casdin · Director
  • Heinrich Dreismann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in CA, CO, FL, MA, NJ, NY, RI, TX

Remarks in the notice

  • On the use of proceeds: “The proceeds from the private offering will be used for general working capital purposes, including payments to employees. The officers listed in Item 3 will be among the employees whose salary may be paid from a portion of the proceeds.”

Signed by Jonathan E. Lim, President & CEO. Source: SEC Form D, newest notice filed Nov 12, 2013. Read the notice at the SEC.

equitySEC
Oct 2013$30 MIssued in a merger or acquisition$10 to $50 million

Ignyta, Inc.: Private sale, Oct 2013

Investors in this round

27 investors had bought by the notice of Nov 12, 2013: 26 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jonathan Lim · Executive Officer, Director
  • Patrick O'Connor · Executive Officer
  • Zachary Hornby · Executive Officer
  • Alexander Casdin · Director
  • Heinrich Dreismann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Shares of common stock issued in exchange for the cancellation of equity of Ignyta Operating, Inc. upon the closing of a reverse merger transaction with such entity.”

Signed by Jonathan E. Lim, President & CEO. Source: SEC Form D, newest notice filed Nov 12, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ignyta, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2015).

    SEC Form D · Nov 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2015

That is all the official record says: Ignyta, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ignyta, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 195 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ignyta, Inc.
NameRoleNamed in
Bernard E. ParkerChief Commercial OfficerNov 2015
Igor P. Bilinsky, Ph.D.General Manager, Immuno-Oncology and Senior Vice President, Special OperationsNov 2015
Jacob E. Chacko, M.D.Chief Financial OfficerNov 2015
Jonathan E. Lim, M.D.President and Chief Executive OfficerNov 2015
Matt E. Onaitis, J.D.Secretary and General CounselNov 2015
Pratik S. Multani, M.D.Chief Medical OfficerNov 2015
Robert E. Wild, Ph.D.Chief Scientific Officer and SVP, ResearchNov 2015
Valerie S. Harding, Ph.D.Senior Vice President, Chemistry, Manufacturing and ControlsNov 2015
Zachary E. HornbyChief Operating OfficerNov 2015
Jonathan LimExecutive officerDec 2013
Patrick O'ConnorExecutive officerDec 2013
Zachary HornbyExecutive officerDec 2013
Alex E. CasdinDirectorNov 2015
Heiner E. Dreismann, Ph.D.DirectorNov 2015
James E. Bristol, Ph.D.DirectorNov 2015
James E. Freddo, M.D.DirectorNov 2015
Jonathan E. Lim, M.D.President and Chief Executive OfficerNov 2015
Alexander CasdinDirectorDec 2013
Heinrich DreismannDirectorDec 2013
Jonathan LimDirectorDec 2013